A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.

NCT05917470 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
21
Enrollment
INDUSTRY
Sponsor class

Stopped Oncternal Therapeutics, Inc. announced on 12 SEP 2024 its decision to discontinue its clinical trials evaluating ONCT-534, its dual action androgen receptor inhibitor for the treatment of patients with metastatic castration resistant cancer.

Conditions

Interventions

Sponsor

Oncternal Therapeutics, Inc